Drug name - Arcapta Neohaler

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(2 years from now)

CN1156451C NOVARTIS Adrenoreceptor Agonist
Jun, 2020

(2 years ago)

CN1353692A NOVARTIS Adrenoreceptor Agonist
Jun, 2020

(2 years ago)

IN222346B NOVARTIS Beta2-Adrenoceptor Agonists
Jun, 2020

(2 years ago)

IN200101673P4 NOVARTIS Beta 2-Adrenoceptor Agonists
Jun, 2020

(2 years ago)

EP2332915A1 NOVARTIS Beta2-Adrenoceptor Agonists
Jun, 2020

(2 years ago)

EP2332915B1 NOVARTIS Beta2-Adrenoceptor Agonists
Jun, 2020

(2 years ago)

EP1183240A1 NOVARTIS Beta2-Adrenoceptor Agonists
Nov, 2024

(2 years from now)

EP1183240B1 NOVARTIS Beta2-Adrenoceptor Agonists
Nov, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device Oct, 2028

(6 years from now)

Drugs and Companies using INDACATEROL MALEATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 75MCG BASE POWDER;INHALATION Discontinued

availability in other generic markets.

Click on the highlighted region to filter.